Abstracts tagged "Biologicals"

Abstract Number: 0080 • ACR Convergence 2022
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
Juan Ruiz¹, Chi-Fang Wu², Hui Zhao², Sharon Giordano², Suja Rajan³ and Maria Suarez-Almazor⁴, ¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX, ⁴MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic and targeted synthetic disease modifying antirheumatic drugs (bDMARD and tsDMARD) are immunosuppressant, and there have been concerns that they might impact tumor immunity…
Abstract Number: 0308 • ACR Convergence 2022
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Joseph Merola¹, Kristina Callis-Duffin², Byron Padilla³, Cuiyong Yue⁴, Huzefa Photowala⁴, Blair Kaplan⁴ and Iain B McInnes⁵, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³AbbVie, Inc., Waukegan, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…
Abstract Number: 0414 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Xenofon Baraliakos¹, Fabiana Ganz², Hideto Kameda³, Jessica Walsh⁴, Manish Jain⁵, Kristin D’Silva⁶, Peter Wung⁶, Xianwei Bu⁶, Jayne Stigler⁶ and Désirée van der Heijde⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²AbbVie, Inc., Luzern, Switzerland, ³Toho University, Tokyo, Japan, ⁴University of Utah, Salt Lake City, UT, ⁵Great Lakes Clinical Trials, Chicago, IL, ⁶AbbVie, Inc., North Chicago, IL, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has been evaluated in the treatment of AS both in patients (pts) naïve to biologic DMARDs (bDMARDs)1…
Abstract Number: 0595 • ACR Convergence 2022
Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
Janani Sundaresan¹, Ittai B. Muller¹, Marry Lin¹, Floris P.J.G. Lafeber², Paco Welsing², Maurits C.F.J. De Rotte³, Maja Bulatovic-Calasan⁴, Conny van der Laken⁵, Robert De Jonge⁶ and Gerrit Jansen⁵, ¹Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Clinical Chemistry, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUmc, Amsterdam, The Netherlands; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁶Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Tocilizumab (TCZ), a biologic Disease Modifying Anti-Rheumatic Drug, elicits an immune-modulating effect by binding to the interleukin 6 receptor and inhibiting downstream signaling. Despite…
Abstract Number: 0812 • ACR Convergence 2022
3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry
Jasmin B. Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Prasad T. Oommen³, Ales Janda⁴, Juergen Rech⁵, Catharina Schuetz⁶, Tilmann Kallinich⁷, Frank Weller-Heinemann⁸, Gerd Horneff⁹, Ivan Foeldvari¹⁰, Florian Meier¹¹, Michael Borte¹², Tobias Krickau¹³, Julia Weber-Arden¹⁴ and Norbert Blank¹⁵, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Division of Nephrology, University of Marburg, Marburg, Germany, ³Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ⁵University Clinic Erlangen, Erlangen, Germany, ⁶Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ⁷Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁸Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ⁹Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁰Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹¹Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ¹²ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, ¹³Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ¹⁴Novartis Pharma GmbH, Nuernberg, Germany, ¹⁵Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Cryopyrin-associated periodic syndromes (CAPS) are monogenic autoinflammatory diseases with severe systemic inflammation. The IL-1β inhibitor canakinumab (CAN) leads to a rapid remission of CAPS…
Abstract Number: 0978 • ACR Convergence 2022
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
Muhammad Shipa¹, liliana ribeiro santos², Dao X Nguyen¹, Andrew Embleton-Thirsk¹, Mariea parvaz¹, David Isenberg¹, Caroline Gordon³ and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²University College London, London, ³Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The results from the BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We…
Abstract Number: 1159 • ACR Convergence 2022
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Ana De Vicente-Delmás¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, David Martínez-López², Alba Herrero-Morant⁴, Eva Galíndez-Agirregoikoa⁵, Nuria Barroso-García⁶, Natalia Palmou-Fontana², Miguel Ángel González-Gay⁷ and Ricardo Blanco⁸, ¹Hospital General Santa María del Puerto, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ⁷Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1795 • ACR Convergence 2022
Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
Julien Damart¹, Silvia Sirotti², Mariano Andrès³, Edoardo Cipolletta⁴, Georgios Filippou⁵, Davide Carboni⁶, Emilio Filippucci⁷, Pilar Diez⁸, Abhishek Abhishek⁹, Augustin Latourte¹⁰, Hang-Korng Ea¹¹, Sebastien Ottaviani¹², Jean-Guillaume Letarouilly¹³, Renaud Desbarbieux¹⁴, Sahara Graf¹, Laurène Norberciak¹, Pascal Richette¹⁵ and Tristan Pascart¹⁶, ¹Hôpital Saint-Philibert, Lomme, France, ²Università degli Studi di Milano, Milano, Italy, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Polytechnic University of Marche, Ancona, Italy, ⁵Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, ⁶Luigi Sacco University, Milano, Italy, ⁷Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, ⁸Alicante University, Alicante, Spain, ⁹University of Nottingham, Nottingham, United Kingdom, ¹⁰Université de Paris, Paris, France, ¹¹Lariboisière Hospital, Paris, France, ¹²Hopital Bichat-Claude Bernard, Paris, France, ¹³CHU Lille, Lille, France, ¹⁴Ch Boulogne-sur-Mer, Boulogne-sur-Mer, France, ¹⁵Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹⁶Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease lacks recommendations on treatment strategies. This study reports on treatment modalities used in European tertiary hospitals for the management…
Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Laure Gossec¹, Mohamed Sharaf², Elke Theander³, Marlies Neuhold⁴, Paul Bergmans⁵, May Shawi⁶, Michelle Perate⁷, Christine Contré⁸ and Laura Coates⁹, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ³Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Formerly at Janssen, Breda, Netherlands, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
Abstract Number: 2192 • ACR Convergence 2022
Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Leah K. Flatman¹, Yvan St. Pierre², Isabelle Malhamé³, Olga Basso¹, Anick Berard⁴, Sasha Bernatsky² and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴University of Montreal, Montréal, QC, Canada
Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
Abstract Number: 0105 • ACR Convergence 2022
Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
Archanaa Murugan¹, Ximena Ruiz² and Leslie Harris Jr.¹, ¹University of Alabama at Birmingham- Internal Medicine- Montgomery, Montgomery, AL, ²University of Alabama at Birmingham- Division of Clinical Immunology and Rheumatology, Montgomery, AL
Background/Purpose: Immunosuppressive states can attenuate the immunogenicity of the COVID-19 vaccines. Some studies have shown an improved immune response with a supplemental primary dose. In…
Abstract Number: 0309 • ACR Convergence 2022
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Eugen Feist¹, Evgeny Nasonov², Michael Luggen³, Saeed Fatenejad⁴, Sergey Grishin⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴SFC Medica, LLC, Charlotte, NC, ⁵R-Pharm, Moscow, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…
Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Casper Webers¹, Augusta Ortolan², Alexandre Sepriano³, Louise Falzon⁴, Xenofon Baraliakos⁵, Robert Landewé⁶, Sofia Ramiro⁷, Désirée van der Heijde⁸ and Elena Nikiphorou⁹, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²University of Padova/Leiden University Medical Center, Padova, Italy, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁹Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…
Abstract Number: 0623 • ACR Convergence 2022
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
Edoardo Prediletto¹, Cankut Cubuk², Elena Pontarini³, Felice Rivellese², Alessandra Nerviani², Davide Lucchesi³, Mattia Caliste¹, Elisa Corsiero¹, Manzoor Ahmed³, rebecca hands³, Myles Lewis², Costantino Pitzalis² and Michele Bombardieri⁴, ¹Wlliam Harvey Research Institute Queen Mary University on London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³William Harvey Research Institute, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom
Background/Purpose: Despite advances in the treatment of Rheumatoid Arthritis (RA), synthetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].